What is Caidya?
Caidya operates as a global clinical research organization, specializing in supporting innovators across various therapeutic areas. The company provides a broad spectrum of clinical services, underpinned by extensive therapeutic expertise and proprietary clinical technology designed to ensure trial transparency and facilitate data-driven decision-making. Caidya's operational scope covers the entire drug development lifecycle, assisting partners from initial strategy and clinical development to regulatory submission and ongoing market surveillance, positioning it as a key player in accelerating therapeutic advancements.
How much funding has Caidya raised?
Caidya has raised a total of $297.8M across 14 funding rounds:
Debt
$13M
Debt
$3M
Debt
$4M
Private Equity
$50M
Private Equity
$3.7M
Debt
$3M
Private Equity
$10M
Debt
$18.4M
Debt
$2M
Other Financing Round
$165M
Debt (2012): $13M, investors not publicly disclosed
Debt (2014): $3M with participation from Undisclosed
Debt (2014): $4M, investors not publicly disclosed
Private Equity (2015): $50M supported by Hatteras Venture Partners, Virgo Investment Group, LLC, and Crestline Investors, Inc.
Private Equity (2016): $3.7M, investors not publicly disclosed
Debt (2017): $3M backed by Undisclosed
Private Equity (2017): $10M, investors not publicly disclosed
Debt (2020): $18.4M, investors not publicly disclosed
Debt (2020): $2M supported by PPP
Other Financing Round (2025): $165M featuring Rubicon Founders
Key Investors in Caidya
Rubicon Founders
Rubicon Founders is an entrepreneurial healthcare investment firm dedicated to building and growing transformational companies. The firm focuses on investing and partnering to create meaningful businesses that deliver enduring value by revolutionizing healthcare delivery.
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm that invests in early-stage companies, particularly those in the life sciences and technology sectors. They are known for providing strategic guidance and capital to help portfolio companies achieve significant growth and market impact.
Emergent Growth Fund
Emergent Growth Fund is an investment firm focused on providing capital to emerging companies, likely with an emphasis on technology and life sciences. Their investment strategy aims to support companies with high growth potential and innovative business models.
What's next for Caidya?
The recent major strategic investment in Caidya signals a phase of accelerated growth and potential expansion of its service offerings and technological capabilities. This significant backing, particularly in the context of its overall funding history, suggests the company is well-positioned to scale its operations, enhance its global reach, and potentially pursue strategic partnerships or acquisitions. The focus on delivery excellence and an elevated customer experience, combined with advanced clinical technology, indicates a strategic intent to solidify its market leadership and drive innovation within the clinical research sector.
See full Caidya company page
